Idazoxan

Summary

Idazoxan (CHEMBL10316) is a phase-3 clinical-stage small-molecule α-adrenergic antagonist targeting ADRA2A, ADRA2B, and ADRA2C; indicated across 2 conditions including major depressive disorder and alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 3 (ADRA2A, ADRA2B, ADRA2C)
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 204.22 Da · C11H12N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL10316
Name	Idazoxan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	54459
ChEBI	CHEBI:5862
Molecular formula	C11H12N2O2
Molecular weight	204.22
InChIKey	HPMRFMKYPGXPEP-UHFFFAOYSA-N

SMILES: C1CN=C(N1)C2COC3=CC=CC=C3O2

IUPAC name: 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole

ChEBI definition: A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.

Pharmacological roles (ChEBI): α-adrenergic antagonist.

Also known as: Dl-idazoxan, Idazoxan, Idazoxano, NSC-759867, Racemic idazoxan, RX-781094, idazoxan, idazoxane, SID26751897, SID90341761, SID104171177, SID144203724

Parent form; salt/anhydrous children: CHEMBL543467

Patent coverage: 1,200 distinct patent families (4,279 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,202 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA2A	α2A-adrenoceptor	Antagonist	8	0.1%	P08913
ADRA2B	α2B-adrenoceptor	Antagonist	7.6	0.2%	P18089
ADRA2C	α2C-adrenoceptor	Antagonist	7.7	0%	P18825

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Adrenergic receptor alpha-2, Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, Monoamine oxidase, Alpha-1A adrenergic receptor, Serine/threonine-protein kinase mTOR, Aldehyde dehydrogenase 1A1, Nischarin, Alpha-2A adrenergic receptor, Alpha-1A adrenergic receptor.

Bioactivity

ChEMBL activities: 73 potent at pChembl ≥ 5 of 80 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q28838	8.82	Ki	1.5	nM	CHEMBL_ACT_1177186
P19328	8.76	Ki	1.72	nM	CHEMBL_ACT_890273
P19328	8.64	Kd	2.29	nM	CHEMBL_ACT_505908
P19328	8.56	Kd	2.75	nM	CHEMBL_ACT_337789
ADRA2A	8.4	Kd	3.98	nM	CHEMBL_ACT_390594
ADRA2A	8.35	Ki	4.47	nM	CHEMBL_ACT_23231358
P19328	8.29	Kd	5.13	nM	CHEMBL_ACT_612326
ADRA2A	8.15	Ki	7.08	nM	CHEMBL_ACT_2459904
ADRA2A	8.15	Ki	7.08	nM	CHEMBL_ACT_8058403
P19328	8.12	Ki	7.59	nM	CHEMBL_ACT_741675
P19328	8.11	Kd	7.76	nM	CHEMBL_ACT_1001731
P19328	8.11	Kd	7.76	nM	CHEMBL_ACT_389741
P19328	8.11	Kd	7.76	nM	CHEMBL_ACT_389748
NISCH	8.1	Ki	7.94	nM	CHEMBL_ACT_111986
ADRA2A	8.1	Ki	8	nM	CHEMBL_ACT_2020364
ADRA2A	8.08	IC50	8.32	nM	CHEMBL_ACT_968817
P19328	8.07	Kd	8.51	nM	CHEMBL_ACT_336702
P19328	8.04	Kd	9.12	nM	CHEMBL_ACT_321128
P19328	8.04	Kd	9.12	nM	CHEMBL_ACT_729282
P19328	8.01	Kd	9.77	nM	CHEMBL_ACT_50833
P19328	8	Ki	10	nM	CHEMBL_ACT_1001730
P19328	8	Ki	10	nM	CHEMBL_ACT_389740
P19328	8	Ki	10	nM	CHEMBL_ACT_389746
P19328	7.96	Ki	10.96	nM	CHEMBL_ACT_248492
P19328	7.96	Ki	10.96	nM	CHEMBL_ACT_390593
P19328	7.96	Ki	10.96	nM	CHEMBL_ACT_741674
P19328	7.93	Kd	11.75	nM	CHEMBL_ACT_890274
ADRA2C	7.75	Ki	17.78	nM	CHEMBL_ACT_2459945
ADRA2C	7.75	Ki	17.78	nM	CHEMBL_ACT_8058421
P19328	7.73	Kd	18.62	nM	CHEMBL_ACT_1177188
ADRA2C	7.72	Ki	19	nM	CHEMBL_ACT_2020366
ADRA2B	7.71	IC50	19.5	nM	CHEMBL_ACT_968818
P19328	7.68	IC50	21	nM	CHEMBL_ACT_170912
ADRA2B	7.64	Ki	22.91	nM	CHEMBL_ACT_2459925
ADRA2B	7.64	Ki	22.91	nM	CHEMBL_ACT_8058412
MAOA	7.55	Ki	28	nM	CHEMBL_ACT_1123266
P19328	7.49	Kd	32.36	nM	CHEMBL_ACT_336705
ADRA2A	7.41	Kd	38.9	nM	CHEMBL_ACT_336704
ADRA2A	7.29	Ki	51.29	nM	CHEMBL_ACT_1923959
ADRA2A	7.29	Ki	51.29	nM	CHEMBL_ACT_2500575
ADRA2A	7.28	Kd	52.48	nM	CHEMBL_ACT_890275
ADRA2C	7.27	IC50	53.7	nM	CHEMBL_ACT_968819
ADRA2B	7	Ki	100	nM	CHEMBL_ACT_2020365
ADRA1D	6.85	Kd	141.2	nM	CHEMBL_ACT_336706
P15823	6.58	Ki	261	nM	CHEMBL_ACT_389745
P15823	6.57	Kd	269.1	nM	CHEMBL_ACT_505910
NISCH	6.52	Ki	300	nM	CHEMBL_ACT_481508
P15823	6.48	Ki	332	nM	CHEMBL_ACT_1001733
P15823	6.42	Kd	380.2	nM	CHEMBL_ACT_1001734
P15823	6.42	Kd	380.2	nM	CHEMBL_ACT_389747
P15823	6.39	Ki	403	nM	CHEMBL_ACT_890272
P18130	6.3	Ki	500	nM	CHEMBL_ACT_1177187
P15823	6.3	Kd	501.2	nM	CHEMBL_ACT_612327
P15823	6.16	Kd	691.8	nM	CHEMBL_ACT_321129
P15823	6.16	Kd	691.8	nM	CHEMBL_ACT_729283
P15823	6.1	Kd	794.3	nM	CHEMBL_ACT_1177189
P15823	6.1	Ki	794.3	nM	CHEMBL_ACT_248491
P15823	6.1	Kd	794.3	nM	CHEMBL_ACT_337790
P15823	6.1	Ki	794.3	nM	CHEMBL_ACT_390592
P15823	6.1	Ki	794.3	nM	CHEMBL_ACT_741673
MAOA	6	IC50	1000	nM	CHEMBL_ACT_16268107
MAOB	6	IC50	1000	nM	CHEMBL_ACT_16283362
MAOA	6	IC50	1000	nM	CHEMBL_ACT_26581794
MAOB	6	IC50	1000	nM	CHEMBL_ACT_26581866
P15823	6	Kd	1000	nM	CHEMBL_ACT_336703
P15823	5.98	Kd	1047	nM	CHEMBL_ACT_50832
Q4G017	5.9	Ki	1259	nM	CHEMBL_ACT_16610435
NISCH	5.9	Ki	1255	nM	CHEMBL_ACT_2563370
NISCH	5.9	Ki	1256	nM	CHEMBL_ACT_2564061
P15823	5.78	IC50	1650	nM	CHEMBL_ACT_170913
ADRA1A	5.54	IC50	2884	nM	CHEMBL_ACT_968816
MTOR	5.33	Potency	4645	nM	CHEMBL_ACT_4522133
MTOR	5.18	Potency	6561	nM	CHEMBL_ACT_3919367

Target pathways

Aggregated over 3 target gene(s): ADRA2A, ADRA2B, ADRA2C.

Top Reactome pathways

19 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	3	ADRA2A, ADRA2B, ADRA2C
Signal Transduction	3	ADRA2A, ADRA2B, ADRA2C
Signaling by GPCR	3	ADRA2A, ADRA2B, ADRA2C
Class A/1 (Rhodopsin-like receptors)	3	ADRA2A, ADRA2B, ADRA2C
Amine ligand-binding receptors	3	ADRA2A, ADRA2B, ADRA2C
GPCR downstream signalling	3	ADRA2A, ADRA2B, ADRA2C
Adrenoceptors	3	ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor	3	ADRA2A, ADRA2B, ADRA2C
G alpha (i) signalling events	3	ADRA2A, ADRA2B, ADRA2C
G alpha (z) signalling events	3	ADRA2A, ADRA2B, ADRA2C
GPCR ligand binding	3	ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation	3	ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)	3	ADRA2A, ADRA2B, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Metabolism of proteins	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C

Dominant GO biological processes

GO term	Targets
epidermal growth factor receptor signaling pathway	3
G protein-coupled receptor signaling pathway	3
negative regulation of norepinephrine secretion	3
regulation of vasoconstriction	3
platelet activation	3
negative regulation of epinephrine secretion	3
positive regulation of MAPK cascade	3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	3
adrenergic receptor signaling pathway	3
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	3
regulation of smooth muscle contraction	3
signal transduction	3
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	2
female pregnancy	2
negative regulation of insulin secretion	2

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
major depressive disorder	3	MONDO:0002009	MONDO:0002009

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
EARLY_PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00294944	PHASE3	WITHDRAWN	The Effectiveness of Idazoxan in Treating TRD
NCT02323217	EARLY_PHASE1	COMPLETED	I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
NCT02874820	EARLY_PHASE1	TERMINATED	I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

607 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
Almotriptan	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CHENODIOL	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
NAPHAZOLINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ALFUZOSIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
AMISULPRIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
APRACLONIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BENFLUOREX	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BENZBROMARONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BENZQUINAMIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BENZTHIAZIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BENZTROPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BITHIONOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BRIMONIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
BROMPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CABERGOLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CHLOROQUINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CINNARIZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CLONIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DANAZOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DARIFENACIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DEXMEDETOMIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DOBUTAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DOTHIEPIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
DROPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ECONAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
GUANABENZ	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
GUANFACINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
HALOPROGIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
HYDROXYCHLOROQUINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
HYDROXYZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
ILOPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
INDORAMIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
IPRINDOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
LABETALOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
LOFEXIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
LORCASERIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
LURASIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MAPROTILINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MEBEVERINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
METHYLERGONOVINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
METHYSERGIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MIRTAZAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MOLINDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MONTELUKAST	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MOXISYLYTE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
MOXONIDINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
NEBIVOLOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C
OXICONAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C